Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
01.07. | Harmony Biosciences Holdings, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
25.06. | Harmony Biosciences Acknowledges U.S. Food & Drug Administration (FDA) Action Denying The Citizen Petition For WAKIX (pitolisant) | 79 | PR Newswire | FDA confirms the favorable benefit-risk profile of WAKIX
Harmony Biosciences focused on continuing to advance its pipeline assets across three rare CNS franchises; anticipates at least one new product... ► Artikel lesen | |
24.06. | Harmony Biosciences Receives U.S. Food And Drug Administration Approval For Wakix (pitolisant) In Pediatric Patients With Narcolepsy | 94 | PR Newswire | PLYMOUTH MEETING, Pa., June 24, 2024 /PRNewswire/ -- Harmony Biosciences (Nasdaq: HRMY) today announced that the U.S. Food and Drug Administration (FDA) has approved its supplemental New Drug Application... ► Artikel lesen | |
21.06. | A Glimpse Into The Expert Outlook On Harmony Biosciences Through 7 Analysts | 3 | Benzinga.com | ||
21.06. | Harmony Bio gains as Citi starts at Buy on risk-reward setup | 2 | Seeking Alpha | ||
18.06. | DelveInsight Business Research, LLP: Obesity Market to Observe Impressive Growth by 2034, Assesses DelveInsight | Key Companies - Novo Nordisk A/S, Pfizer, Boehringer Ingelheim, Eli Lilly and Company, Rhythm Pharmaceuticals, Harmony Biosciences | 743 | PR Newswire | The obesity market size is projected to witness growth from 2024 to 2034 due to the rising prevalence of obesity. This expansion is expected to be further influenced by the extensive pipeline... ► Artikel lesen | |
05.06. | Harmony Biosciences Presents Positive Data For Pitolisant In The Treatment Of Excessive Daytime Sleepiness And Fatigue In Myotonic Dystrophy Type 1 | 64 | PR Newswire | PLYMOUTH MEETING, Pa., June 5, 2024 /PRNewswire/ -- Harmony Biosciences (Nasdaq: HRMY) presented data from its Phase 2 signal detection study showing that pitolisant reduced excessive daytime sleepiness... ► Artikel lesen | |
29.05. | Harmony Biosciences Holdings, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
30.04. | Harmony Biosciences Expands It CNS-Focused Pipeline With Epilepsy Candidate, Q1 Earnings Beat Street View | 2 | Benzinga.com | ||
30.04. | Harmony Biosciences Holdings Inc reports results for the quarter ended in March - Earnings Summary | 1 | Reuters | ||
30.04. | Key Takeaways From Harmony Biosciences Analyst Ratings | 1 | Benzinga.com | ||
30.04. | Harmony Biosciences acquires Epygenix gaining rare epilepsy pipeline | 2 | Seeking Alpha | ||
30.04. | Harmony Biosciences Holdings, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
30.04. | Harmony Biosciences Holdings, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
30.04. | Harmony Biosciences Non-GAAP EPS of $0.88 beats by $0.10, revenue of $154.6M misses by $0.19M | 2 | Seeking Alpha | ||
30.04. | Harmony Biosciences Reports Strong First Quarter Financial Results and Acceleration of Its Growth Strategy; Advances Pitolisant Franchise to Extend Revenue Potential Beyond 2040; Strenghtens Sleep/Wake Leadership and Diversifies Into Rare Epilepsy | 136 | GlobeNewswire (Europe) | WAKIX® (pitolisant) Net Revenue of $154.6 Million for First Quarter 2024; ~30% Growth Year-over-Year Supplemental New Drug Application for Pitolisant in Idiopathic Hypersomnia Planned for Second Half... ► Artikel lesen | |
30.04. | Harmony Biosciences Acquires Epygenix Therapeutics, Inc., Adding Late-Stage Epilepsy Franchise to Growing Pipeline of Innovative CNS Assets | 130 | PR Newswire | Lead Candidate, EPX-100, Holds Orphan Drug and Rare Pediatric Disease Designations
EPX-100 in Pivotal Registrational Trial for Dravet Syndrome; Topline Data Expected in 2026
Plan to Initiate Phase... ► Artikel lesen | |
29.04. | Harmony Biosciences Q1 2024 Earnings Preview | 1 | Seeking Alpha | ||
11.04. | Harmony Biosciences Holdings, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
11.04. | Harmony Biosciences Announces Exclusive Agreement To Develop And Commercialize Tpm-1116, A Highly Potent And Selective Oral Orexin-2 Receptor Agonist | 146 | PR Newswire | PLYMOUTH MEETING, Pa., April 11, 2024 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced an exclusive licensing agreement with Bioprojet to develop, manufacture and... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
EPIGENOMICS | 0,650 | +3,83 % | EQS-Adhoc: Epigenomics AG: Vorläufiges Halbjahresergebnis zum 30. Juni 2024 | EQS-Ad-hoc: Epigenomics AG / Schlagwort(e): Halbjahresergebnis
Epigenomics AG: Vorläufiges Halbjahresergebnis zum 30. Juni 2024
22.07.2024 / 17:49 CET/CEST
Veröffentlichung einer Insiderinformation... ► Artikel lesen | |
CRISPR THERAPEUTICS | 52,75 | -1,40 % | Is a Beat in the Cards for CRISPR Therapeutics (CRSP) in Q2 Earnings? | ||
MAINZ BIOMED | 0,323 | +2,87 % | EQS-News: Mainz BioMed N.V.: Mainz Biomed bringt verbesserten ColoAlert-Darmkrebstest mit modernsten Funktionen zur Optimierung der Screening-Effizienz und Benutzerfreundlichkeit auf den Markt | Emittent / Herausgeber: Mainz BioMed N.V.
/ Schlagwort(e): Sonstiges
Mainz Biomed bringt verbesserten ColoAlert-Darmkrebstest mit modernsten Funktionen zur Optimierung der Screening-Effizienz... ► Artikel lesen | |
DEFENCE THERAPEUTICS | 0,556 | +2,96 % | EQS-News: Defence Therapeutics Inc.: Defence Therapeutics erhält Unterstützung durch das CNRI-H-Projekt von Canadian Nuclear Laboratories zur Beschleunigung der Entwicklung seines Radioimmunokonjugat-Programms | EQS-News: Defence Therapeutics Inc.
/ Schlagwort(e): Sonstiges
DEFENCE THERAPEUTICS ERHÄLT UNTERSTÜTZUNG DURCH DAS CNRI-H-PROJEKT VON CANADIAN NUCLEAR LABORATORIES... ► Artikel lesen | |
NEUROCRINE BIOSCIENCES | 135,50 | +0,26 % | Neurocrine Biosciences Launches INGREZZA SPRINKLE Capsules | WASHINGTON (dpa-AFX) - Neurocrine Biosciences (NBIX) announced the launch of a new sprinkle formulation of INGREZZA capsules for the treatment of adults with tardive dyskinesia and chorea associated... ► Artikel lesen | |
HALOZYME THERAPEUTICS | 51,68 | -0,19 % | Halozyme Therapeutics, Inc.: Halozyme Announces argenx Receives FDA Approval for VYVGART Hytrulo Co-Formulated with ENHANZE for Chronic Inflammatory Demyelinating Polyneuropathy | VYVGART® Hytrulo is the first and only neonatal Fc receptor (FcRn) blocker that is delivered as a subcutaneous injection, approved to treat chronic inflammatory demyelinating polyneuropathy (CIDP)
CIDP... ► Artikel lesen | |
GINKGO BIOWORKS | 0,316 | -7,60 % | Ginkgo (DNA) to Report Q2 Earnings: What's in the Cards? | ||
BEAM THERAPEUTICS | 33,140 | +3,02 % | Beam Therapeutics Stock Earns RS Rating Jump To 85 | ||
ARGENX | 454,60 | -0,26 % | argenx SE: argenx Reports Half Year 2024 Financial Results and Provides Second Quarter Business Update | $478 million in second quarter global net product sales First CIDP patients treated with VYVGART® Hytrulo following June 21st FDA approval On track to begin four additional registrational studies... ► Artikel lesen | |
ONCOLYTICS BIOTECH | 0,935 | 0,00 % | Oncolytics Biotech® Inc.: Oncolytics Biotech® to Host Conference Call to Discuss Second Quarter Financial Results and Recent Operational Highlights | Conference call and webcast to take place on Thursday, August 1, 2024, at 4:30 p.m. ET
SAN DIEGO, Calif. and CALGARY, Alberta, July 24, 2024 /PRNewswire/ -- Oncolytics Biotech® Inc.... ► Artikel lesen | |
RECURSION PHARMACEUTICALS | 8,350 | +3,73 % | DelveInsight Business Research, LLP: Vascular Malformations Market to Grow Substantially by 2034, Assesses DelveInsight | Key Companies - ARTham Therapeutics, Neurelis, Protara Therapeutics, Recursion, Genentech, Vascular Therapies, Palvella Therapeutics | Vascular malformations represent one of the largest and most underserved segments. The current Atreatment options are limited. The market size of vascular malformations is expected to increase... ► Artikel lesen | |
ARDELYX | 5,156 | -0,31 % | Ardelyx, Inc.: Ardelyx, AAKP and NMQF File Lawsuit to Protect Dialysis Patient Choice and Timely Access to Clinically Meaningful Medicines | Lawsuit challenges CMS's statutory overreach in its determination to include oral-only phosphate-lowering therapies in the End-Stage Renal Disease Prospective Payment System Inclusion of oral-only... ► Artikel lesen | |
ASSERTIO | 1,505 | +2,38 % | Assertio Holdings, Inc. to Report Second Quarter 2024 Financial Results on August 7, 2024 | ||
ARCTURUS THERAPEUTICS | 24,030 | +4,57 % | Arcturus Therapeutics Holdings Inc.: Arcturus Therapeutics Provides Updates for Ornithine Transcarbamylase (OTC) Deficiency and Cystic Fibrosis (CF) Programs | ARCT-810 Phase 2 study completed enrollment at 0.3 mg/kg dose level in Europe with data expected later this year ARCT-810 to expand Phase 2 clinical program in the U.S. to enroll patients with... ► Artikel lesen | |
VIR BIOTECHNOLOGY | 10,700 | +0,38 % | Vir Biotechnology Stock Reaches 80-Plus RS Rating Benchmark |